Speciality Medicines approved its draft directors' report for FY26 and scheduled its fifth annual general meeting for September 28, 2026. The board meeting concluded on September 3, 2026.

The company's Board of Directors held the meeting at its corporate office in Mumbai. The session began at 3:00 pm and ended at 3:40 pm. Directors considered and approved the draft directors' report along with annexures and other reports to be included in the Annual Report 2025-26.

AGM Details

The company decided to call its fifth Annual General Meeting on Monday, September 28, 2026, at 11:00 am IST. The event will be conducted through video conferencing or other audio-visual means in compliance with Ministry of Corporate Affairs and SEBI circulars.

Since the entire shareholding is in dematerialised form, the register of members and share transfer books will not be closed. Members recorded in the register of beneficial owners maintained by depositories as on September 21, 2026, are entitled to remote e-voting facilities.

Appointments

The board appointed National Securities Depository Limited as the remote e-voting agency for resolutions proposed at the AGM. Additionally, CS Hardikkumar Jetani was appointed as the scrutinizer to conduct the voting process in a fair and transparent manner.

The notice of the AGM and the annual report for FY26 will be submitted to the exchange once dispatched to shareholders via email.

Speciality Medicines Limited has secured regulatory approval from the competent health authority in Ethiopia for two additional speciality pharmaceutical formulations. The approvals, announced on August 12, 2026, cover Olanzapine Tablets 5 mg (brand name Olazyn 5) and Diazepam Tablets 5 mg (brand name Diazem 5).

The new registrations strengthen the company's export footprint in the African region. With these additions, Speciality Medicines now holds 12 registered formulations in Ethiopia. Including its existing registrations in Peru, the company's total global registered product portfolio stands at 14 formulations.

Product Registration Details

The newly approved products fall under the central nervous system (CNS) therapeutic category. Both formulations carry a validity period of five years.

Strategic Significance

The approvals reflect continued progress in Speciality Medicines' international registration strategy across Africa and Latin America. The addition of Olazyn 5 and Diazem 5 expands the range of speciality products available to overseas partners within the CNS segment.

The company continues to pursue additional international filings, with formulations currently under regulatory review across multiple overseas markets as part of its broader export expansion strategy.

Management Commentary

Sumit Goyani, Whole-Time Director, stated that the approvals mark another step forward in strengthening the company's presence in Ethiopia and expanding its speciality portfolio across international markets. He noted that Ethiopia remains an important market, with these registrations strengthening the product range offered through overseas partners.

Goyani added that the regulatory and quality teams continue working on additional filings and approvals across target export geographies, aiming to deepen international presence and support long-term export growth.

About the Company

Incorporated in 2021, Speciality Medicines Ltd is a speciality pharmaceutical company engaged in the marketing, distribution, and international commercialization of high-value pharmaceutical formulations. The company focuses on key therapeutic areas including oncology, immunology, neurology, and rare diseases, offering a diversified portfolio of speciality medicines across multiple dosage forms.